Lactosylated Liposomes for Targeted Delivery of Doxorubicin to Hepatocellular Carcinoma

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2012 Oct 25

PMID 23093902

Citations 32

Authors

Xiaoju Zhou

Mengzi Zhang

Bryant Yung

Hong Li

Chenguang Zhou

L James Lee

Robert J Lee

Affiliations

Soon will be listed here.

Abstract

Background: N-lactosyl-dioleoylphosphatidylethanolamine (Lac-DOPE) was synthesized and evaluated as a liver-specific targeting ligand via asialoglycoprotein receptors for liposomal delivery of doxorubicin.

Methods: Lactosylated liposomes encapsulating calcein (Lac-L-calcein) or doxorubicin (Lac-L-DOX) composed of egg phosphatidylcholine, cholesterol, monomethoxy polyethylene glycol 2000-distearoyl phosphatidylethanolamine, and Lac-DOPE at 50:35:5:10 (mol/mol) were prepared by polycarbonate membrane extrusion and evaluated in human hepatocellular carcinoma HepG2 cells. Cellular uptake of Lac-L-calcein was monitored by confocal microscopy and by flow cytometry. The cytotoxicity of Lac-L-DOX was evaluated by MTT assay. The pharmacokinetic properties of Lac-L-DOX were studied in normal mice, and its biodistribution and antitumor activity were studied in nude mice with HepG2 xenografts.

Results: The size of Lac-L-DOX was less than 100 nm and the liposomes demonstrated excellent colloidal stability. In vitro uptake of Lac-L-calcein by HepG2 cells was four times greater than that of non-targeted L-calcein. In the presence of 20 mM lactose, the uptake of Lac-L-calcein was inhibited, suggesting that asialoglycoprotein receptors mediated the observed cellular uptake. Lac-L-DOX exhibited enhanced in vivo cytotoxicity compared with the nontargeted liposomal doxorubicin (L-DOX), and its pharmacokinetic parameters indicate that Lac-L-DOX has a long blood circulation time (t(1/2) 8.73 hours). Tissue distribution and therapeutic efficacy studies in nude mice bearing HepG2 xenografts show that Lac-L-DOX had significantly stronger tumor inhibitory activity compared with L-DOX and free doxorubicin, along with a higher accumulation of drug within the tumor site and greater cellular uptake by tumor cells.

Conclusion: These data suggest that lactosylated liposomes are promising drug delivery vehicles for hepatocellular carcinoma.

Citing Articles

Lactosylated lipid calcium phosphate-based nanoparticles: A promising approach for efficient DNA delivery to hepatocytes.

Khalifeh M, Badiee A, Ramezanian N, Sahebkar A, Farahpour A, Kazemi Oskuee R Iran J Basic Med Sci. 2024; 27(8):952-958.

PMID: 38911238 PMC: 11193503. DOI: 10.22038/IJBMS.2024.76683.16602.

Improved Targeting and Safety of Doxorubicin through a Novel Albumin Binding Prodrug Approach.

Liu Y, Corrales-Guerrero S, Kuo J, Robb R, Nagy G, Cui T ACS Omega. 2024; 9(1):977-987.

PMID: 38222540 PMC: 10785662. DOI: 10.1021/acsomega.3c07163.

Nanotechnology in the Diagnostic and Therapy of Hepatocellular Carcinoma.

Graur F, Puia A, Mois E, Moldovan S, Pusta A, Cristea C Materials (Basel). 2022; 15(11).

PMID: 35683190 PMC: 9182427. DOI: 10.3390/ma15113893.

Liposomes: structure, composition, types, and clinical applications.

Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W Heliyon. 2022; 8(5):e09394.

PMID: 35600452 PMC: 9118483. DOI: 10.1016/j.heliyon.2022.e09394.

Fabrication and characterization of a folic acid-bound 5-fluorouracil loaded quantum dot system for hepatocellular carcinoma targeted therapy.

Shi X, He D, Tang G, Tang Q, Xiong R, Ouyang H RSC Adv. 2022; 8(35):19868-19878.

PMID: 35541013 PMC: 9080723. DOI: 10.1039/c8ra01025k.

References

Tagami T, Ernsting M, Li S . Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. J Control Release. 2011; 152(2):303-9. DOI: 10.1016/j.jconrel.2011.02.009. View

Seymour L, Ferry D, Anderson D, Hesslewood S, Julyan P, Poyner R . Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002; 20(6):1668-76. DOI: 10.1200/JCO.2002.20.6.1668. View

Yan X, Scherphof G, Kamps J . Liposome opsonization. J Liposome Res. 2005; 15(1-2):109-39. DOI: 10.1081/lpr-64971. View

Gabizon A, Papahadjopoulos D . Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988; 85(18):6949-53. PMC: 282096. DOI: 10.1073/pnas.85.18.6949. View

Wang S, Deng Y, Xu H, Wu H, Qiu Y, Chen D . Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin. Eur J Pharm Biopharm. 2005; 62(1):32-8. DOI: 10.1016/j.ejpb.2005.07.004. View

Gabizon A . Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992; 52(4):891-6. View

Laginha K, Verwoert S, Charrois G, Allen T . Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005; 11(19 Pt 1):6944-9. DOI: 10.1158/1078-0432.CCR-05-0343. View

Mayer L, Tai L, Ko D, Masin D, GINSBERG R, Cullis P . Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 1989; 49(21):5922-30. View

Bernardes G, Kikkeri R, Maglinao M, Laurino P, Collot M, Hong S . Design, synthesis and biological evaluation of carbohydrate-functionalized cyclodextrins and liposomes for hepatocyte-specific targeting. Org Biomol Chem. 2010; 8(21):4987-96. DOI: 10.1039/c0ob00372g. View

10.

Managit C, Kawakami S, Yamashita F, Hashida M . Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes. J Pharm Sci. 2005; 94(10):2266-75. DOI: 10.1002/jps.20443. View

11.

Gewirtz D . A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999; 57(7):727-41. DOI: 10.1016/s0006-2952(98)00307-4. View

12.

Marks D, Belov L, Davey M, Davey R, Kidman A . The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leuk Res. 1992; 16(12):1165-73. DOI: 10.1016/0145-2126(92)90114-m. View

13.

Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z . The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2008; 30(2):226-32. DOI: 10.1016/j.biomaterials.2008.09.014. View

14.

Allen T . Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci. 1994; 15(7):215-20. DOI: 10.1016/0165-6147(94)90314-x. View

15.

Higuchi Y, Oka M, Kawakami S, Hashida M . Mannosylated semiconductor quantum dots for the labeling of macrophages. J Control Release. 2007; 125(2):131-6. DOI: 10.1016/j.jconrel.2007.10.007. View

16.

Hattori Y, Kawakami S, Yamashita F, Hashida M . Controlled biodistribution of galactosylated liposomes and incorporated probucol in hepatocyte-selective drug targeting. J Control Release. 2000; 69(3):369-77. DOI: 10.1016/s0168-3659(00)00338-2. View

17.

Longmuir K, Haynes S, Baratta J, Kasabwalla N, Robertson R . Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate. Int J Pharm. 2009; 382(1-2):222-33. PMC: 2784200. DOI: 10.1016/j.ijpharm.2009.07.030. View

18.

Hong R, Huang C, Tseng Y, Pang V, Chen S, Liu J . Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?. Clin Cancer Res. 1999; 5(11):3645-52. View

19.

Safra T, Muggia F, Jeffers S, Tsao-Wei D, Groshen S, Lyass O . Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol. 2000; 11(8):1029-33. DOI: 10.1023/a:1008365716693. View

20.

Lee R, Low P . Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1995; 1233(2):134-44. DOI: 10.1016/0005-2736(94)00235-h. View